Safety Profile of High IgPro20 Infusion Parameters in Patients with Primary Immunodeficiency (PID): Results from The Forced Upward Titration HILO Study

The Hizentra Label Optimization (HILO) study (NCT03033745) assessed safety and tolerability of increasing infusion rates/volumes of subcutaneous IgPro20 (Hizentra ®) in PID patients.

Source: Journal of Allergy and Clinical Immunology - January 31, 2020 Category: Allergy & Immunology Authors: Mikhail Rojavin, Chengping Hu, John Anderson, Vincent Bonagura, Juthaporn Cowan, Patricia Lugar, Paul Maglione, Shahzad Mustafa, Niraj Patel, John Routes, Panida Sriaroon, Donald VINH, Jutta Hofmann Source Type: research